# QBitaLabs Due Diligence Preparation Guide

**CONFIDENTIAL**

*Materials and Information for Investor Due Diligence*

---

## Due Diligence Overview

This document outlines all materials and information that QBitaLabs should prepare for investor due diligence during the Series A fundraising process. Thorough preparation will accelerate the process and demonstrate organizational maturity.

---

## Section 1: Corporate Documents

### 1.1 Formation & Governance

| Document | Status | Location |
|----------|--------|----------|
| Certificate of Incorporation | âœ… Ready | /legal/corporate/ |
| Bylaws | âœ… Ready | /legal/corporate/ |
| Board meeting minutes | âœ… Ready | /legal/board/ |
| Stockholder meeting minutes | âœ… Ready | /legal/shareholders/ |
| Current cap table | âœ… Ready | Carta |
| Stock option plan (equity incentive) | âœ… Ready | /legal/equity/ |
| Stock option grants | âœ… Ready | Carta |
| Authorized shares resolution | âœ… Ready | /legal/corporate/ |

### 1.2 Prior Financing Documents

| Document | Status | Notes |
|----------|--------|-------|
| Seed round term sheet | âœ… Ready | $2M, Q3 2025 |
| Seed round purchase agreement | âœ… Ready | SAFE notes |
| Investor rights agreement | âœ… Ready | Standard NVCA |
| Voting agreement | â³ Draft | To be executed |
| Pro forma cap table | â³ Draft | Post-Series A |

### 1.3 Organizational Chart

```
                    Board of Directors
                          â”‚
                         CEO
                          â”‚
        â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”´â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
        â”‚            â”‚         â”‚            â”‚
       CTO          CSO       COO         CFO
        â”‚            â”‚     (to hire)    (to hire)
   â”Œâ”€â”€â”€â”€â”´â”€â”€â”€â”€â”       â”‚
Engineering  Product Science
```

---

## Section 2: Financial Information

### 2.1 Historical Financials

| Document | Period | Status |
|----------|--------|--------|
| Income statement | 2024-2025 | âœ… Ready |
| Balance sheet | Current | âœ… Ready |
| Cash flow statement | 2024-2025 | âœ… Ready |
| Monthly burn report | Last 12 months | âœ… Ready |
| Bank statements | Last 6 months | âœ… Ready |

### 2.2 Projections & Models

| Document | Status | Notes |
|----------|--------|-------|
| 5-year financial model | âœ… Ready | See /planning/financials/ |
| Revenue assumptions | âœ… Ready | Documented |
| Headcount plan | âœ… Ready | By quarter |
| Use of funds breakdown | âœ… Ready | Series A |
| Scenario analysis | âœ… Ready | Bull/base/bear |

### 2.3 Key Metrics Dashboard

| Metric | Current | Target |
|--------|---------|--------|
| MRR | $50K | $200K (Q4) |
| ARR | $600K | $5M (Year 1) |
| Gross margin | 65% | 75% |
| Monthly burn | $400K | $600K |
| Runway | 18 months | 24 months |
| Headcount | 15 | 35 |

---

## Section 3: Intellectual Property

### 3.1 Patent Portfolio

| Title | Status | Filing Date | Number |
|-------|--------|-------------|--------|
| Quantum-Neuromorphic Hybrid Processing | Pending | 2025-06-15 | US 2025/XXXXXX |
| SWARM Coordination for Molecular Sim | Pending | 2025-08-20 | US 2025/XXXXXX |
| Digital Twin Multi-scale Modeling | Draft | Q2 2026 | - |
| Neuromorphic Biosignal Processing | Draft | Q2 2026 | - |

### 3.2 Trade Secrets

| Category | Description | Protection |
|----------|-------------|------------|
| Algorithms | VQE optimization routines | Employee NDAs |
| Training data | 50+ molecular models | Access controls |
| Architecture | Hybrid processing design | Code security |

### 3.3 Open Source Usage

| Component | License | Risk |
|-----------|---------|------|
| Qiskit | Apache 2.0 | Low |
| PennyLane | Apache 2.0 | Low |
| NumPy | BSD | Low |
| FastAPI | MIT | Low |
| PyTorch | BSD | Low |

### 3.4 IP Assignment

| Document | Status |
|----------|--------|
| Founder IP assignment | âœ… Complete |
| Employee invention assignment | âœ… In employment agreements |
| Contractor IP assignment | âœ… In contractor agreements |
| Prior employer clearance | âœ… Founders cleared |

---

## Section 4: Technology & Product

### 4.1 Product Documentation

| Document | Status | Location |
|----------|--------|----------|
| Product roadmap | âœ… Ready | /docs/roadmap/ |
| Technical architecture | âœ… Ready | /docs/architecture/ |
| API documentation | âœ… Ready | /docs/api/ |
| User documentation | â³ In progress | /docs/user/ |

### 4.2 Technology Stack

| Layer | Technology | Maturity |
|-------|------------|----------|
| Quantum | Qiskit, Cirq, PennyLane | Production |
| Neuromorphic | Akida, custom SNN | Beta |
| ML/AI | PyTorch, NumPy | Production |
| Backend | FastAPI, PostgreSQL | Production |
| Infrastructure | AWS, Kubernetes | Production |

### 4.3 Security & Compliance

| Certification | Status | Timeline |
|---------------|--------|----------|
| SOC 2 Type I | â³ In progress | Q2 2026 |
| SOC 2 Type II | ğŸ“‹ Planned | Q4 2026 |
| HIPAA | â³ In progress | Q2 2026 |
| GDPR | âœ… Compliant | Current |
| ISO 27001 | ğŸ“‹ Planned | 2027 |

### 4.4 Technical Demo Materials

| Demo | Description | Duration |
|------|-------------|----------|
| Platform overview | Architecture walkthrough | 15 min |
| Molecular simulation | VQE drug-target binding | 20 min |
| Digital twin | Patient model creation | 15 min |
| API integration | Developer experience | 10 min |

---

## Section 5: Commercial Traction

### 5.1 Customer Pipeline

| Stage | Count | Value | Notes |
|-------|-------|-------|-------|
| Prospect | 25 | $15M | Identified targets |
| Engaged | 12 | $8M | Active discussions |
| POC | 3 | $750K | Paid pilots |
| LOI | 3 | $3M | Verbal commits |
| Closed | 0 | $0 | First close expected Q2 |

### 5.2 Customer References

*Available upon request with customer permission:*

- [Fortune 500 Pharma] - Discovery pilot, 6 months
- [Major Health System] - Digital twin evaluation
- [Biotech Startup] - Lead optimization project

### 5.3 Partnership Documentation

| Partner | Type | Status | Value |
|---------|------|--------|-------|
| [Cloud Provider] | Technology | LOI | Infrastructure credits |
| [Quantum Hardware] | Technology | In discussion | Hardware access |
| [Consulting Firm] | Channel | In discussion | Joint go-to-market |

### 5.4 Case Studies

| Customer | Use Case | Results |
|----------|----------|---------|
| Pilot A | Virtual screening | 10x speed improvement |
| Pilot B | Lead optimization | 95% accuracy vs. 80% baseline |
| Pilot C | Digital twin | 20% better outcome prediction |

---

## Section 6: Team & HR

### 6.1 Leadership Team

| Name | Role | Background | Equity |
|------|------|------------|--------|
| [CEO] | CEO/Co-founder | [Pharma] VP, MIT PhD | 25% |
| [CTO] | CTO/Co-founder | Google X, Quantum | 20% |
| [CSO] | CSO/Co-founder | Pfizer, Novartis | 15% |

### 6.2 Employee Roster

| Role | Count | Avg Tenure | Key Hires |
|------|-------|------------|-----------|
| Engineering | 8 | 14 months | [Names] |
| Science | 4 | 12 months | [Names] |
| Product | 2 | 10 months | [Names] |
| Operations | 1 | 6 months | [Names] |

### 6.3 HR Documentation

| Document | Status |
|----------|--------|
| Employment agreements | âœ… All signed |
| Offer letters | âœ… Standardized |
| Employee handbook | âœ… Current |
| Equity vesting schedules | âœ… In Carta |
| Benefits summary | âœ… Current |
| Background checks | âœ… Completed |

### 6.4 Advisory Board

| Advisor | Expertise | Compensation |
|---------|-----------|--------------|
| [Name] | Quantum chemistry | 0.25% equity |
| [Name] | FDA regulatory | $5K/month |
| [Name] | Pharma strategy | 0.25% equity |
| [Name] | Healthcare systems | Advisory shares |

---

## Section 7: Legal & Compliance

### 7.1 Material Contracts

| Contract | Counterparty | Value | Expiry |
|----------|--------------|-------|--------|
| Cloud services | AWS | $100K/year | Annual |
| Office lease | [Landlord] | $50K/year | 2027 |
| Software licenses | Various | $30K/year | Annual |
| Pilot agreements | [Customers] | $250K | 2026 |

### 7.2 Litigation & Claims

| Status | Description |
|--------|-------------|
| âœ… None | No pending litigation |
| âœ… None | No threatened claims |
| âœ… None | No regulatory investigations |

### 7.3 Insurance

| Policy | Coverage | Provider |
|--------|----------|----------|
| D&O | $5M | [Carrier] |
| E&O | $2M | [Carrier] |
| Cyber | $5M | [Carrier] |
| General liability | $2M | [Carrier] |

### 7.4 Regulatory Filings

| Filing | Status | Notes |
|--------|--------|-------|
| FDA pre-submission | ğŸ“‹ Planned Q2 | Regulatory strategy |
| State registrations | âœ… Complete | DE, CA, NY |
| Tax filings | âœ… Current | 2024 filed |

---

## Section 8: Market & Competition

### 8.1 Market Research

| Document | Status |
|----------|--------|
| TAM/SAM/SOM analysis | âœ… Ready |
| Competitive landscape | âœ… Ready |
| Customer interviews | âœ… 15 completed |
| Industry reports | âœ… McKinsey, BCG, etc. |

### 8.2 Competitive Analysis

| Competitor | Strengths | Weaknesses | Our Advantage |
|------------|-----------|------------|---------------|
| Recursion | Scale, data | Classical only | Quantum accuracy |
| SchrÃ¶dinger | Reputation | Legacy tech | Modern platform |
| QuEra | Quantum | No healthcare | Domain expertise |

---

## Section 9: Data Room Organization

### Recommended Structure

```
QBitaLabs Data Room/
â”œâ”€â”€ 1_Corporate/
â”‚   â”œâ”€â”€ Formation/
â”‚   â”œâ”€â”€ Governance/
â”‚   â””â”€â”€ Cap_Table/
â”œâ”€â”€ 2_Financial/
â”‚   â”œâ”€â”€ Historical/
â”‚   â”œâ”€â”€ Projections/
â”‚   â””â”€â”€ Metrics/
â”œâ”€â”€ 3_Legal/
â”‚   â”œâ”€â”€ IP/
â”‚   â”œâ”€â”€ Contracts/
â”‚   â””â”€â”€ Compliance/
â”œâ”€â”€ 4_Technology/
â”‚   â”œâ”€â”€ Architecture/
â”‚   â”œâ”€â”€ Product/
â”‚   â””â”€â”€ Security/
â”œâ”€â”€ 5_Commercial/
â”‚   â”œâ”€â”€ Customers/
â”‚   â”œâ”€â”€ Partnerships/
â”‚   â””â”€â”€ Marketing/
â”œâ”€â”€ 6_Team/
â”‚   â”œâ”€â”€ Leadership/
â”‚   â”œâ”€â”€ Employees/
â”‚   â””â”€â”€ Advisors/
â””â”€â”€ 7_Market/
    â”œâ”€â”€ Research/
    â””â”€â”€ Competition/
```

### Data Room Platforms

| Platform | Cost | Features |
|----------|------|----------|
| DocSend | $45/mo | Tracking, watermarks |
| Carta | Included | Cap table integration |
| Google Drive | Free | Basic sharing |
| Dropbox | $20/mo | Standard sharing |

**Recommendation**: DocSend for investor-facing materials with tracking

---

## Section 10: Due Diligence Process

### Timeline (Target: 4-6 weeks)

| Week | Activity | Owner |
|------|----------|-------|
| 1 | Initial data room access | CEO |
| 1-2 | Financial review | CFO (fractional) |
| 2-3 | Technical deep dive | CTO |
| 2-3 | Legal review | Legal counsel |
| 3-4 | Customer references | CEO |
| 4-5 | Final questions | All |
| 5-6 | Term sheet negotiation | CEO + counsel |

### Key Contact Points

| Area | Primary | Backup |
|------|---------|--------|
| Corporate/Finance | CEO | Legal counsel |
| Technology | CTO | VP Engineering |
| Science/Product | CSO | Head of Product |
| Commercial | CEO | VP Sales (future) |
| HR/Team | COO (future) | CEO |

### Common DD Questions

**Technology**
- How does your quantum approach differ from classical ML?
- What's your hardware dependency strategy?
- How do you ensure reproducibility of results?

**Commercial**
- What's your customer acquisition process?
- Who are your first 5 target customers?
- What's your pricing strategy and how did you determine it?

**Financial**
- What are your key assumptions in the model?
- What's driving the path to profitability?
- How does usage-based pricing scale?

**Team**
- What key hires are planned post-funding?
- How do you attract quantum talent?
- What's your equity philosophy?

---

## Appendix: Document Checklist

### Pre-DD (Must Have)

- [x] Pitch deck (12 slides)
- [x] Executive summary
- [x] Financial model (5-year)
- [x] Cap table
- [x] Team bios
- [x] Product demo

### DD-Ready (Have Available)

- [x] Certificate of Incorporation
- [x] Bylaws
- [x] Prior financing docs
- [x] Customer LOIs/contracts
- [x] Employment agreements
- [x] Patent applications
- [x] Technical architecture
- [x] Security documentation

### DD-Requested (Prepare on Demand)

- [ ] Board minutes (all)
- [ ] Bank statements
- [ ] Tax returns
- [ ] Insurance policies
- [ ] Vendor contracts
- [ ] Customer references
- [ ] Technical audit results

---

*This document should be updated weekly during active fundraising.*
